KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Common Equity (2019 - 2025)

Historic Common Equity for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $9.6 billion.

  • Royalty Pharma's Common Equity fell 621.54% to $9.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.6 billion, marking a year-over-year decrease of 621.54%. This contributed to the annual value of $10.3 billion for FY2024, which is 255.92% up from last year.
  • Latest data reveals that Royalty Pharma reported Common Equity of $9.6 billion as of Q3 2025, which was down 621.54% from $9.5 billion recorded in Q2 2025.
  • Over the past 5 years, Royalty Pharma's Common Equity peaked at $10.4 billion during Q3 2022, and registered a low of $9.5 billion during Q2 2025.
  • Over the past 5 years, Royalty Pharma's median Common Equity value was $9.9 billion (recorded in 2024), while the average stood at $10.0 billion.
  • Per our database at Business Quant, Royalty Pharma's Common Equity soared by 3733.71% in 2021 and then tumbled by 798.07% in 2023.
  • Quarter analysis of 5 years shows Royalty Pharma's Common Equity stood at $10.2 billion in 2021, then decreased by 7.06% to $9.5 billion in 2022, then grew by 5.87% to $10.1 billion in 2023, then rose by 2.56% to $10.3 billion in 2024, then dropped by 6.98% to $9.6 billion in 2025.
  • Its Common Equity stands at $9.6 billion for Q3 2025, versus $9.5 billion for Q2 2025 and $9.8 billion for Q1 2025.